Quest Diagnostics (STU:QDI) Cyclically Adjusted Revenue per Share: €76.33 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:QDI Quest Diagnostics Inc STU:QDI
77 GF Score
Price €206.90
GF Value €171.44
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Quest Diagnostics Cyclically Adjusted Revenue per Share?

Quest Diagnostics STU:QDI +4.34% 77 Cyclically Adjusted Revenue per Share is €76.33 as of Jun. 2026. GuruFocus rates STU:QDI with a GF Score™ of 77/100 and a GF Value™ of €171.44 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Quest Diagnostics's adjusted revenue per share for the three months ended in Jun. 2026 was €23.368. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €76.33 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Quest Diagnostics's average Cyclically Adjusted Revenue Growth Rate was 7.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Quest Diagnostics was 10.00% per year. The lowest was 4.30% per year. And the median was 7.10% per year.

As of today (2026-09-15), Quest Diagnostics's current stock price is €206.90. Quest Diagnostics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €76.33. Quest Diagnostics's Cyclically Adjusted PS Ratio of today is 2.71.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Quest Diagnostics was 2.79. The lowest was 1.36. And the median was 2.05.


Quest Diagnostics  (STU:QDI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Quest Diagnostics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=206.90/76.33
=2.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Quest Diagnostics was 2.79. The lowest was 1.36. And the median was 2.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Quest Diagnostics Cyclically Adjusted Revenue per Share Related Terms


Quest Diagnostics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Quest Diagnostics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest Diagnostics Cyclically Adjusted Revenue per Share Chart

Quest Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.96 65.29 66.89 75.53 71.14

Quest Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.78 69.59 71.14 73.89 76.33

STU:QDI vs LH, MTD, GH: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Quest Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest Diagnostics Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Quest Diagnostics's Cyclically Adjusted PS Ratio falls into.


STU:QDI
77GF Score
Quest Diagnostics Inc STU:QDI
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quest Diagnostics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Quest Diagnostics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=23.368/333.9520*333.9520
=23.368

Current CPI (Jun. 2026) = 333.9520.

Quest Diagnostics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 11.895 241.428 16.454
201612 12.240 241.432 16.931
201703 12.091 243.801 16.562
201706 12.099 244.955 16.495
201709 11.295 246.819 15.282
201712 11.396 246.524 15.438
201803 11.028 249.554 14.758
201806 11.587 251.989 15.356
201809 11.684 252.439 15.457
201812 11.764 251.233 15.637
201903 12.246 254.202 16.088
201906 12.780 256.143 16.662
201909 12.841 256.759 16.702
201912 12.791 256.974 16.623
202003 12.251 258.115 15.850
202006 12.199 257.797 15.803
202009 17.409 260.280 22.337
202012 18.380 260.474 23.565
202103 16.728 264.877 21.090
202106 16.668 271.696 20.487
202109 18.825 274.310 22.918
202112 19.205 278.802 23.004
202203 19.235 287.504 22.343
202206 19.342 296.311 21.799
202209 20.916 296.808 23.534
202212 19.901 296.797 22.392
202303 19.226 301.836 21.272
202306 18.844 305.109 20.625
202309 18.505 307.789 20.078
202312 18.832 306.746 20.502
202403 19.464 312.332 20.811
202406 19.879 314.175 21.130
202409 20.043 315.301 21.229
202412 21.744 315.605 23.008
202503 22.299 319.799 23.286
202506 21.557 322.561 22.318
202509 21.324 324.800 21.925
202512 21.525 324.054 22.182
202603 22.094 330.213 22.344
202606 23.368 333.952 23.368

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €76.33 mean?
Quest Diagnostics (STU:QDI) has a Cyclically Adjusted Revenue per Share of €76.33 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Quest Diagnostics and its competitors.
Is Quest Diagnostics' Cyclically Adjusted Revenue per Share too high?
Quest Diagnostics' current Cyclically Adjusted Revenue per Share is €76.33. Overall, Quest Diagnostics has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' Cyclically Adjusted Revenue per Share compare to LH and MTD?
Quest Diagnostics' Cyclically Adjusted Revenue per Share of €76.33 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Quest Diagnostics and its competitors. Quest Diagnostics's current Cyclically Adjusted Revenue per Share is €76.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (STU:QDI) is currently considered Modestly Overvalued. The stock's GF Value™ is €171.44, compared to a current price of €206.90 — trading 20.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €76.33. Quest Diagnostics' overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Quest Diagnostics (STU:QDI), the current Cyclically Adjusted Revenue per Share is €76.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Quest Diagnostics (STU:QDI) Overvalued in 2026?

Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued. The current stock price of €206.90 is trading 20.7% above its estimated GF Value™ of €171.44. GuruFocus considers Quest Diagnostics to be Modestly Overvalued.

Key valuation signals for STU:QDI:

  • Cyclically Adjusted Revenue per Share: €76.33
  • GF Value™: €171.44 vs. price of €206.90 (20.7% above fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the STU:QDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Quest Diagnostics Business Description

Address 500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
77GF Score

Get the complete analysis for STU:QDI

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€206.90
Price
€171.44
GF Value